This article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.
"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.
“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
"The goal of this narrative is to share details and lessons learned during our on-call urology coverage in the midst of the current pandemic so we can help others by informing planning," write Alexander Small, MD, and Rich Matulewicz, MD.
Types of patients with muscle invasive bladder cancer who may be candidates for a watch-and-wait approach.
Avelumab (Bavencio) as a maintenance treatment after chemotherapy significantly extended overall survival in patients with advanced urothelial cancer, according to findings from thephase III JAVELIN Bladder 100 trial.
Advances in endourology have made kidney-sparing treatments a viable treatment option.
The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.